Hypersensitivity - Pipeline Review, H2 2016

  • ID: 3939711
  • Report
  • 313 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Alfacyte Ltd
  • Antigen Express, Inc.
  • Biomay AG
  • EpiVax, Inc.
  • Japan Tobacco Inc.
  • Roxall Medizin GmbH
  • MORE
Hypersensitivity - Pipeline Review, H2 2016

Summary

‘Hypersensitivity - Pipeline Review, H2 2016’, provides an overview of the Hypersensitivity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
- The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
- The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypersensitivity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypersensitivity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Alfacyte Ltd
  • Antigen Express, Inc.
  • Biomay AG
  • EpiVax, Inc.
  • Japan Tobacco Inc.
  • Roxall Medizin GmbH
  • MORE
Introduction

Hypersensitivity Overview

Therapeutics Development

Hypersensitivity - Therapeutics under Development by Companies

Hypersensitivity - Therapeutics under Investigation by Universities/Institutes

Hypersensitivity - Pipeline Products Glance

Hypersensitivity - Products under Development by Companies

Hypersensitivity - Products under Investigation by Universities/Institutes

Hypersensitivity - Companies Involved in Therapeutics Development

Hypersensitivity - Therapeutics Assessment

Drug Profiles

Hypersensitivity - Dormant Projects

Hypersensitivity - Discontinued Products

Hypersensitivity - Product Development Milestones

Appendix

Number of Products under Development for Hypersensitivity, H2 2016

Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Development by Companies, H2 2016 (Contd..8)

Products under Investigation by Universities/Institutes, H2 2016

Hypersensitivity - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016

Hypersensitivity - Pipeline by Adverum Biotechnologies, Inc., H2 2016

Hypersensitivity - Pipeline by Aimmune Therapeutics, Inc., H2 2016

Hypersensitivity - Pipeline by Alfacyte Ltd, H2 2016

Hypersensitivity - Pipeline by ALK-Abello A/S, H2 2016

Hypersensitivity - Pipeline by Allakos Inc., H2 2016

Hypersensitivity - Pipeline by Allergopharma GmbH & Co. KG, H2 2016

Hypersensitivity - Pipeline by Allergy Therapeutics Plc, H2 2016

Hypersensitivity - Pipeline by Amgen Inc., H2 2016

Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016

Hypersensitivity - Pipeline by AnaptysBio, Inc., H2 2016

Hypersensitivity - Pipeline by Anergis SA, H2 2016

Hypersensitivity - Pipeline by Antigen Express, Inc., H2 2016

Hypersensitivity - Pipeline by Aravax Pty Ltd, H2 2016

Hypersensitivity - Pipeline by Array BioPharma Inc., H2 2016

Hypersensitivity - Pipeline by ASIT biotech s.a., H2 2016

Hypersensitivity - Pipeline by AskAt Inc., H2 2016

Hypersensitivity - Pipeline by Astellas Pharma Inc., H2 2016

Hypersensitivity - Pipeline by BioLingus AG, H2 2016

Hypersensitivity - Pipeline by Biomay AG, H2 2016

Hypersensitivity - Pipeline by Biotec Pharmacon ASA, H2 2016

Hypersensitivity - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Hypersensitivity - Pipeline by Circassia Pharmaceuticals Plc, H2 2016

Hypersensitivity - Pipeline by DBV Technologies S.A., H2 2016

Hypersensitivity - Pipeline by DNJ Pharma, Inc., H2 2016

Hypersensitivity - Pipeline by EA Pharma Co Ltd, H2 2016

Hypersensitivity - Pipeline by Enzene Biosciences Ltd., H2 2016

Hypersensitivity - Pipeline by EpiVax, Inc., H2 2016

Hypersensitivity - Pipeline by Fountain Biopharma Inc., H2 2016

Hypersensitivity - Pipeline by HAL Allergy BV, H2 2016

Hypersensitivity - Pipeline by iCeutica, Inc., H2 2016

Hypersensitivity - Pipeline by ImmunoFrontier, Inc., H2 2016

Hypersensitivity - Pipeline by Immunomic Therapeutics, Inc., H2 2016

Hypersensitivity - Pipeline by Immupharma Plc, H2 2016

Hypersensitivity - Pipeline by InMed Pharmaceuticals Inc., H2 2016

Hypersensitivity - Pipeline by Interprotein Corporation, H2 2016

Hypersensitivity - Pipeline by Japan Tobacco Inc., H2 2016

Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H2 2016

Hypersensitivity - Pipeline by Laboratorios LETI S.L., H2 2016

Hypersensitivity - Pipeline by Monosol Rx, LLC, H2 2016

Hypersensitivity - Pipeline by NAL Pharmaceuticals Ltd., H2 2016

Hypersensitivity - Pipeline by Neovacs SA, H2 2016

Hypersensitivity - Pipeline by Novartis AG, H2 2016

Hypersensitivity - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Hypersensitivity - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016

Hypersensitivity - Pipeline by REGiMMUNE Corporation, H2 2016

Hypersensitivity - Pipeline by Roxall Medizin GmbH, H2 2016

Hypersensitivity - Pipeline by Sanofi, H2 2016

Hypersensitivity - Pipeline by Sealife PHARMA GMBH, H2 2016

Hypersensitivity - Pipeline by Stallergenes Greer plc, H2 2016

Hypersensitivity - Pipeline by Stallergenes SAS, H2 2016

Hypersensitivity - Pipeline by Swecure AB, H2 2016

Hypersensitivity - Pipeline by Therabron Therapeutics, Inc., H2 2016

Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016

Hypersensitivity - Pipeline by Toleranzia AB, H2 2016

Hypersensitivity - Pipeline by United Biomedical, Inc., H2 2016

Hypersensitivity - Pipeline by United BioPharma, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Hypersensitivity - Dormant Projects, H2 2016

Hypersensitivity - Dormant Projects (Contd..1), H2 2016

Hypersensitivity - Dormant Projects (Contd..2), H2 2016

Hypersensitivity - Dormant Projects (Contd..3), H2 2016

Hypersensitivity - Dormant Projects (Contd..4), H2 2016

Hypersensitivity - Dormant Projects (Contd..5), H2 2016

Hypersensitivity - Dormant Projects (Contd..6), H2 2016

Hypersensitivity - Dormant Projects (Contd..7), H2 2016

Hypersensitivity - Dormant Projects (Contd..8), H2 2016

Hypersensitivity - Dormant Projects (Contd..9), H2 2016

Hypersensitivity - Dormant Projects (Contd..10), H2 2016

Hypersensitivity - Discontinued Products, H2 2016 298List of Figures

Number of Products under Development for Hypersensitivity, H2 2016

Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Alfacyte Ltd
  • Antigen Express, Inc.
  • Biomay AG
  • EpiVax, Inc.
  • Japan Tobacco Inc.
  • Roxall Medizin GmbH
  • MORE
Hypersensitivity Hypersensitivity refers to is a reaction which occurs soon after exposure to allergens. Hypersensitivity diseases have been grouped into four major categories immediate (type I) hypersensitivity, antibody-mediated (type II) hypersensitivity, immune complex-mediated (type III) hypersensitivity and cell-mediated (type IV) hypersensitivity. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes adrenaline (epinephrine), antihistamines, and corticosteroids.

Hypersensitivity pipeline therapeutics constitutes close to 138 molecules. Out of which approximately 122 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 7, 15, 13, 56, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 2 molecules, respectively.

Our latest report Hypersensitivity – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Adamis Pharmaceuticals Corporation
Adverum Biotechnologies, Inc.
Aimmune Therapeutics, Inc.
Alfacyte Ltd
ALK-Abello A/S
Allakos Inc.
Allergopharma GmbH & Co. KG
Allergy Therapeutics Plc
Amgen Inc.
Anacor Pharmaceuticals, Inc.
AnaptysBio, Inc.
Anergis SA
Antigen Express, Inc.
Aravax Pty Ltd
Array BioPharma Inc.
ASIT biotech s.a.
AskAt Inc.
Astellas Pharma Inc.
BioLingus AG
Biomay AG
Biotec Pharmacon ASA
Boehringer Ingelheim GmbH
Circassia Pharmaceuticals Plc
DBV Technologies S.A.
DNJ Pharma, Inc.
EA Pharma Co Ltd
Enzene Biosciences Ltd.
EpiVax, Inc.
Fountain Biopharma Inc.
HAL Allergy BV
iCeutica, Inc.
ImmunoFrontier, Inc.
Immunomic Therapeutics, Inc.
Immupharma Plc
InMed Pharmaceuticals Inc.
Interprotein Corporation
Japan Tobacco Inc.
JW Pharmaceutical Corporation
Laboratorios LETI S.L.
Monosol Rx, LLC
NAL Pharmaceuticals Ltd.
Neovacs SA
Novartis AG
Ono Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals Inc
REGiMMUNE Corporation
Roxall Medizin GmbH
Sanofi
Sealife PHARMA GMBH
Stallergenes Greer plc
Stallergenes SAS
Swecure AB
Therabron Therapeutics, Inc.
Thesan Pharmaceuticals, Inc.
Toleranzia AB
United Biomedical, Inc.
United BioPharma, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll